

*The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.*

Ipsen Biopharmaceuticals, Inc. (“Ipsen”) would like to inform you of the immediate Market Action Product Retrieval of all lots of TAZVERIK® (tazemetostat) tablets (NDC 72607-100-00) from distribution following emerging serious safety concerns identified in an ongoing clinical study. Please see the [“Dear HCP Letter”](#) and [“Dear Patient Letter”](#).

This action is being taken as an urgent safety measure and applies to all TAZVERIK product currently in distribution including at the patient level including product indicated for follicular lymphoma (FL) and epithelioid sarcoma (ES).

An ad hoc safety review by the Independent Data Monitoring Committee (IDMC) for the SYMPHONY-1 (EZH-302) clinical study—evaluating tazemetostat in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma—identified a significant imbalance in hematologic secondary malignancies between treatment arms.

As a result, Ipsen has:

- Directed all study treatment with TAZVERIK be stopped and ceased further enrollment under an Urgent Safety Measure (USM).
- Enacted a Market Action and Product Retrieval of TAZVERIK from the market effective March 9, 2026.

Pharmacy actions requested by Ipsen is to cease all dispensing. Do not dispense remaining TAZVERIK product to any patient. Ipsen requests that pharmacies segregate inventory, immediately quarantine all TAZVERIK stock, and arrange product return with their distributor.

Ipsen requests that pharmacies inform Healthcare Providers (HCPs) to stop prescribing TAZVERIK right away. Send HCPs who have prescribed TAZVERIK the [“Dear HCP Letter”](#) and request that they read the entire letter.

For patients prescribed TAZVERIK, Ipsen requests that pharmacies ask each patient to contact their doctor immediately and inform patients to stop taking TAZVERIK right away. Provide patients with the [“Dear Patient Letter”](#) and request that they read the entire letter.